Low Prevalence of Human Papilloma Virus in Patients with Breast Cancer, Kerman; Iran

Document Type : Research Articles


1 Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran.

2 Department of Medical Microbiology, Kerman University of Medical Sciences, Kerman, Iran.

3 Pathology and Stem Cell Research Center, erman University of Medical Sciences, Kerman, Iran.


Breast cancer is the first of the most important causes of the deaths of women in the world and in Iran. There are
various causes and causes of this cancer, one of which has recently been described as a cause of breast cancer, is the human
papillomavirus (HPV). The HPV is transmitted through sexual contact and skin lesions. There are more than 100 types of
HPV that can influence different parts of the body. Some types of HPV can cause cancer (such as cervical or anal cancer)
and others can cause warts (such as genital or plantar warts). To study the risk of HPV infection in Breast Cancer, we
managed a Case-Control study in Kerman, southeast of Iran. For this purpose, 98 paraffin blocks of breast cancer and
40 paraffin blocks of fibrocystic as a control were tested for the presence of HPV DNA using Real-Time PCR, and
HPV typing was done using INNo-Lippa assay. HPV DNA was detected in 8 out of 98 patients (8.2%), while it was
not detected in the control group samples. HPV types 16, 18 were the most common (62.5%) types in positive samples.
The prevalence of HPV in patients with breast cancer of Iran is very low and less than other regions of the world,
it seems that maybe rout of transmission of HPV in Iran is under control. No one knows exactly why breast cancer
occurs. The environment, hormones, Viruses, or your lifestyle could all play a role in the development of breast cancer.
Currently, Vaccination is the best way to prevent cancer that’s due to HPV. However, additional studies on the larger
group of patients are needed to explain the roles of HPV in Breast cancer.


Main Subjects

Volume 19, Issue 11
November 2018
Pages 3039-3044
  • Receive Date: 25 September 2017
  • Revise Date: 18 August 2018
  • Accept Date: 27 September 2018